This study demonstrates hit-to-lead optimization of SPA, a structurally optimized ester derivative of the marine-derived sipholenol A, as a new antitumor entity with a unique ability to interfere with the interplay of Brk and FAK signaling networks, suggesting its therapeutic potential for the control of highly invasive breast cancers. The gene discussed is PTK6; the disease is breast cancer.